Exogene

Exogene is a UK-based biotechnology startup founded in 2019, specializing in the AI-enabled design of high-affinity, cancer-specific T-cell receptors (TCRs). The company's slogan, "AI-enabled design of high-affinity, cancer-specific T-cell receptors," succinctly captures its core mission. Exogene leverages generative AI and high-throughput lab experiments to develop TCR-based therapies for solid tumors in the biotechnology and pharmaceutical industries. Recently, the company secured a significant $2.00M Seed Round investment on 25 April 2022.

The investment was made by a consortium of notable backers including Entrepreneur First, R42, Unruly Capital, Selvedge Venture, KQ Labs, Jude Gomila, and Nadav Rosenberg. This latest round of funding reflects the confidence of industry-leading investors in Exogene's innovative approach and potential to revolutionize cancer treatment. With a clear focus on leveraging cutting-edge technology to address a critical healthcare challenge, Exogene's unique positioning and recent funding raise position it as a noteworthy player in the biotech startup landscape.